Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review

Institute of Regional Health Services Research, University of Southern Denmark, Odense, Denmark.
Journal of proteomics (Impact Factor: 3.93). 02/2012; 75(10):2758-72. DOI: 10.1016/j.jprot.2012.02.007
Source: PubMed

ABSTRACT The focus of this systematic review is to give an overview of the current status of clinical protein profiling studies using MALDI and SELDI MS platforms in the search for ovarian cancer biomarkers. A total of 34 profiling studies were qualified for inclusion in the review. Comparative analysis of published discriminatory peaks to peaks found in an original MALDI MS protein profiling study was made to address the key question of reproducibility across studies. An overlap was found despite substantial heterogeneity between studies relating to study design, biological material, pre-analytical treatment, and data analysis. About 47% of the peaks reported to be associated to ovarian cancer were also represented in our experimental study, and 34% of these redetected peaks also showed a significant difference between cases and controls in our study. Thus, despite known problems related to reproducibility an overlap in peaks between clinical studies was demonstrated, which indicate convergence toward a set of common discriminating, reproducible peaks for ovarian cancer. The potential of the discriminating protein peaks for clinical use as ovarian cancer biomarkers will be discussed and evaluated. This article is part of a Special Issue entitled: Proteomics: The clinical link.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the lifetimes that increased in breast cancers due to the the early screening programs and new therapeutic strategies, many cases still are being lost due to the metastatic relapses. For this reason, new approaches such as the proteomic techniques have currently become the prime objectives of breast cancer researches. Various omic-based techniques have been applied with increasing success to the molecular characterisation of breast tumours, which have resulted in a more detailed classification scheme and have produced clinical diagnostic tests that have been applied to both the prognosis and the prediction of outcome to the treatment. Implementation of the proteomics-based techniques is also seen as crucial if we are to develop a systems biology approach in the discovery of biomarkers of the early diagnosis, prognosis and prediction of the outcome of the breast cancer therapies. In this review, we discuss the studies that have been conducted thus far, for the discovery of diagnostic, prognostic and predictive biomarkers, and evaluate the potential of the discriminating proteins identified in this research for clinical use as breast cancer biomarkers.
    Current Genomics 11/2010; 11(7):528-36. DOI:10.2174/138920210793175930 · 2.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to detect different substances present in a sample, mass spectrometry is an important option that can be used to answer that question. Thus this method is a standard technique in analytical chemistry laboratories. As the name indicates, mass spectrometers are used for obtaining information about the mass of the sample, in general the mass of its molecules. In all the different techniques and variations of mass spectrometry, ions of the sample are accelerated with help of specially tailored electrical fields and then separated by different means in their mass to charge ratio. One very important method of mass separation is the Time-of-Flight technique (TOF-MS). In this chapter, the development of Time-of-Flight mass spectrometers in recent years regarding their instrumental improvements as well as regarding their applications will be described.
    Advances in Imaging and Electron Physics, Edited by Peter W. Hawkes, 04/2015: chapter Two: pages 25-78; , ISBN: 978-0-12-802254-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have implemented a new quality control (QC) parameter for peptide profiling based on isotopic distributions. This QC parameter is an objective measure and facilitates automatic sorting of large numbers of peptide spectra. Peptides in human serum samples were enriched using reversed-phase C(18)-functionalized magnetic beads using a high-throughput robotic platform. High-resolution MALDI-TOF and ultrahigh resolution MALDI-FTICR mass spectra were obtained and a workflow was developed for automated analysis and evaluation of these profiles. To this end, the isotopic distributions of multiple peptides were quantified from both MALDI-TOF and MALDI-FTICR spectra. Odd peptide isotope distributions in TOF spectra could be rationalized from ultrahigh resolution FTICR spectra that showed overlap of different peptides. The comparison of isotope patterns with estimated polyaveragine distributions was used to calculate a QC value for each single mass spectrum. Sorting these QC values enabled the best MALDI spectrum to be selected from replicate spots. Moreover, using this approach spectra containing high intensities of polymers or other contaminants and lacking peptides of interest can be efficiently removed from a clinical dataset. In general, this method simplifies the exclusion of low quality spectra from further statistical analysis.
    Journal of the American Society for Mass Spectrometry 09/2010; 21(9):1515-25. DOI:10.1016/j.jasms.2010.05.004 · 3.19 Impact Factor